Evidence map›Paper›PMID 25505565›Full record

ArticlePharmacology research & perspectives2013

Antitumor activity of (R,R')-4-methoxy-1-naphthylfenoterol in a rat C6 glioma xenograft model in the mouse.

Michel Bernier, Rajib K Paul, Katina S S Dossou, Artur Wnorowski, Anuradha Ramamoorthy, Arnaud Paris, Ruin Moaddel, Jean-François Cloix, Irving W Wainer

Open access · goldAbstract read
In one paragraph

Article in Pharmacology research & perspectives, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. XCHD Inhibits C6 Cell Growth Primarily via the p53/Caspase Pathway.Evidence-based complementary and alternative medicine : eCAM · 2020
    Article
  4. Article
  5. Concurrent activation of βCellular signalling · 2017
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Michel BernierLaboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health Baltimore, Maryland, 21224.
Rajib K PaulLaboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health Baltimore, Maryland, 21224.
Katina S S DossouLaboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health Baltimore, Maryland, 21224.
Artur WnorowskiLaboratory of Medicinal Chemistry and Neuroengineering, Department of Chemistry, Medical University of Lublin 20-093, Lublin, Poland.
Anuradha RamamoorthyLaboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health Baltimore, Maryland, 21224.
Arnaud ParisInstitut de Chimie Organique et Analytique, ICOA, CNRS UMR7311 BP6759, 45067, Orléans Cedex 2, France.
Ruin MoaddelLaboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health Baltimore, Maryland, 21224.
Jean-François CloixInstitut de Chimie Organique et Analytique, ICOA, CNRS UMR7311 BP6759, 45067, Orléans Cedex 2, France.
Irving W WainerLaboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health Baltimore, Maryland, 21224.
National Institutes of Health · USCentre National de la Recherche Scientifique · FRMedical University of Lublin · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(R,R')-4-methoxy-1-naphthylfenoterol (MNF) inhibits cancer cell proliferation in vitro through cell-type specific modulation of β2-adrenergic receptor and/or cannabinoid receptor function. Here, we report an investigation into antitumor activity of MNF in rat C6 glioma cells. The potent antiproliferative action of MNF in these cells (IC50 of ∼1 nmol/L) was refractory to pharmacological inhibition of β2-adrenergic receptor while a synthetic inverse agonist of cannabinoid receptor 1 significantly blocked MNF activity. The antitumor activity of MNF was then assessed in a C6 glioblastoma xenograft model in mice. Three days after subcutaneous implantation of C6 cells into the lower flank of nude mice, these animals were subjected to i.p. injections of saline or MNF (2 mg/kg) for 19 days and tumor volumes were measured over the course of the experiment. Gene expression analysis, quantitative RT-PCR and immunoblot assays were performed on the tumors after treatment. Significant reduction in mean tumor volumes was observed in mice receiving MNF when compared with the saline-treated group. We identified clusters in expression of genes involved in cellular proliferation, as well as molecular markers for glioblastoma that were significantly downregulated in tumors of MNF-treated mice as compared to saline-injected controls. The efficacy of MNF against C6 glioma cell proliferation in vivo and in vitro was accompanied by marked reduction in the expression of cell cycle regulator proteins. This study is the first demonstration of MNF-dependent chemoprevention of a glioblastoma xenograft model and may offer a potential mechanism for its anticancer action in vivo.

Indexed as

cannabinoid receptorglioma cell lineimmunoblot analysismicroarray analysis(R,R’)-4-methoxy-1-naphthylfenoteroltumor growthxenotransplanted tumor model

Identifiers

PMID25505565
PMCPMC4186428
OpenAlexW2049392651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.